As polygenic risk scores mature, opportunities emerge for disease interception

With comprehensive genetic risk profiling inching closer to clinical use, the biggest opportunity for drug developers could be the new territory it opens up in disease prevention and interception, particularly for common diseases.

Much of industry has piled into Orphan diseases, which are often caused by mutations in single genes, leaving more prevalent, complex diseases lagging...